Table 6 Comparison between pre-treatment SUV, post-treatment SUV, and % change in SUV (∆SUV) of the PD, SD, and PR groups
From: Role of PET/CT in post-therapeutic assessment of bronchogenic carcinoma
Progressive disease | Stable disease | Partial response | P-value | |
|---|---|---|---|---|
Pre-treatment SUV | ||||
Median | 4 | 14.3 | 13.9 | |
IQR | 3.63–8.8 | 9.43–25.78 | 11.7–16.05 | 0.09 |
Range | 3.5–10.4 | 3.5–34.7 | 10–19.19 | |
Post-treatment SUV | ||||
Median | 8.1 | 15.4 | 6 | |
IQR | 7.13–18.68 | 5.6–18.18 | 4.56–6.38 | 0.085 |
Range | 6.8–22.0 | 2–28.2 | 1.1–8.0 | |
∆SUV | ||||
Median | 102.5 | −18.7 | −57.5 | |
IQR | 96.35–110.75 | −44.23 to 7.43 | −75.0 to −51.7 | 0.0008 |
Range | 94.3–113.5 | −54 to 15.4 | −88.9 to −48.3 | |